Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ALOG's Cash to Debt is ranked higher than
87% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.82 vs. ALOG: No Debt )
ALOG' s 10-Year Cash to Debt Range
Min: 1.13   Max: No Debt
Current: No Debt

Equity to Asset 0.84
ALOG's Equity to Asset is ranked higher than
91% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.64 vs. ALOG: 0.84 )
ALOG' s 10-Year Equity to Asset Range
Min: 0.71   Max: 0.88
Current: 0.84

0.71
0.88
Interest Coverage No Debt
ALOG's Interest Coverage is ranked higher than
74% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 94.07 vs. ALOG: No Debt )
ALOG' s 10-Year Interest Coverage Range
Min: 14.38   Max: 9999.99
Current: No Debt

14.38
9999.99
F-Score: 7
Z-Score: 9.31
M-Score: -2.65
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 7.50
ALOG's Operating margin (%) is ranked higher than
82% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.61 vs. ALOG: 7.50 )
ALOG' s 10-Year Operating margin (%) Range
Min: -1.49   Max: 15.02
Current: 7.5

-1.49
15.02
Net-margin (%) 7.97
ALOG's Net-margin (%) is ranked higher than
87% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. ALOG: 7.97 )
ALOG' s 10-Year Net-margin (%) Range
Min: 0.87   Max: 10.5
Current: 7.97

0.87
10.5
ROE (%) 8.35
ALOG's ROE (%) is ranked higher than
80% of the 233 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. ALOG: 8.35 )
ALOG' s 10-Year ROE (%) Range
Min: 0.88   Max: 14.98
Current: 8.35

0.88
14.98
ROA (%) 7.02
ALOG's ROA (%) is ranked higher than
88% of the 261 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. ALOG: 7.02 )
ALOG' s 10-Year ROA (%) Range
Min: 0.68   Max: 11.24
Current: 7.02

0.68
11.24
ROC (Joel Greenblatt) (%) 14.35
ALOG's ROC (Joel Greenblatt) (%) is ranked higher than
80% of the 260 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. ALOG: 14.35 )
ALOG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3.31   Max: 53.33
Current: 14.35

-3.31
53.33
Revenue Growth (3Y)(%) 2.70
ALOG's Revenue Growth (3Y)(%) is ranked higher than
70% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. ALOG: 2.70 )
ALOG' s 10-Year Revenue Growth (3Y)(%) Range
Min: -10.4   Max: 15.9
Current: 2.7

-10.4
15.9
EBITDA Growth (3Y)(%) 9.60
ALOG's EBITDA Growth (3Y)(%) is ranked higher than
83% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. ALOG: 9.60 )
ALOG' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -41.1   Max: 62.5
Current: 9.6

-41.1
62.5
EPS Growth (3Y)(%) 26.90
ALOG's EPS Growth (3Y)(%) is ranked higher than
93% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.30 vs. ALOG: 26.90 )
ALOG' s 10-Year EPS Growth (3Y)(%) Range
Min: -56   Max: 127.6
Current: 26.9

-56
127.6
» ALOG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ALOG Guru Trades in Q4 2013

NWQ Managers 98,030 sh (New)
Steven Cohen 2,786 sh (New)
Chuck Royce 630,555 sh (+20.94%)
Jim Simons 93,554 sh (-14.53%)
Paul Tudor Jones 3,800 sh (-26.92%)
» More
Q1 2014

ALOG Guru Trades in Q1 2014

Joel Greenblatt 39,187 sh (New)
NWQ Managers 211,310 sh (+115.56%)
Paul Tudor Jones 8,000 sh (+110.53%)
Steven Cohen Sold Out
Chuck Royce 614,995 sh (-2.47%)
Jim Simons 21,700 sh (-76.8%)
» More
Q2 2014

ALOG Guru Trades in Q2 2014

Joel Greenblatt 137,675 sh (+251.33%)
NWQ Managers 296,350 sh (+40.24%)
Chuck Royce 634,095 sh (+3.11%)
Paul Tudor Jones 6,700 sh (-16.25%)
Jim Simons 7,354 sh (-66.11%)
» More
Q3 2014

ALOG Guru Trades in Q3 2014

Richard Snow 19,558 sh (New)
Jim Simons 103,054 sh (+1301.33%)
Paul Tudor Jones 11,706 sh (+74.72%)
NWQ Managers 365,630 sh (+23.38%)
Chuck Royce 625,595 sh (-1.34%)
Joel Greenblatt 82,530 sh (-40.05%)
» More
» Details

Insider Trades

Latest Guru Trades with ALOG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 Reduce -40.05%0.05%$64.04 - $78.36 $ 86.521%82530
NWQ Managers 2014-09-30 Add 23.38%0.05%$64.04 - $78.36 $ 86.521%365630
Richard Snow 2014-09-30 New Buy0.04%$64.04 - $78.36 $ 86.521%19558
Joel Greenblatt 2014-06-30 Add 251.33%0.09%$67.78 - $83.97 $ 86.514%137675
NWQ Managers 2014-06-30 Add 40.24%0.07%$67.78 - $83.97 $ 86.514%296350
NWQ Managers 2014-03-31 Add 115.56%0.08%$76.62 - $98.93 $ 86.5-4%211310
Joel Greenblatt 2014-03-31 New Buy0.05%$76.62 - $98.93 $ 86.5-4%39187
NWQ Managers 2013-12-31 New Buy0.08%$83.14 - $97.04 $ 86.5-5%98030
Mario Gabelli 2013-03-31 Sold Out 0.0018%$72.51 - $79.82 $ 86.514%0
Joel Greenblatt 2012-12-31 Sold Out 0.03%$68.06 - $84.1 $ 86.516%0
Joel Greenblatt 2012-09-30 Reduce -76.98%0.09%$61.06 - $80.64 $ 86.528%6111
Joel Greenblatt 2012-06-30 New Buy0.12%$60.06 - $69.31 $ 86.533%26542
Ken Fisher 2012-06-30 Sold Out 0.0037%$60.06 - $69.31 $ 86.533%0
Mario Gabelli 2012-03-31 New Buy$54.59 - $68.67 $ 86.556%3645
Ken Fisher 2012-03-31 New Buy$54.59 - $68.67 $ 86.556%20510
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 26.00
ALOG's P/E(ttm) is ranked higher than
88% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ALOG: 26.00 )
ALOG' s 10-Year P/E(ttm) Range
Min: 10.78   Max: 412.04
Current: 26

10.78
412.04
P/B 2.11
ALOG's P/B is ranked higher than
88% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.46 vs. ALOG: 2.11 )
ALOG' s 10-Year P/B Range
Min: 0.82   Max: 2.53
Current: 2.11

0.82
2.53
P/S 2.08
ALOG's P/S is ranked higher than
81% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.17 vs. ALOG: 2.08 )
ALOG' s 10-Year P/S Range
Min: 0.78   Max: 3.09
Current: 2.08

0.78
3.09
PFCF 31.12
ALOG's PFCF is ranked higher than
86% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ALOG: 31.12 )
ALOG' s 10-Year PFCF Range
Min: 13.81   Max: 1233.52
Current: 31.12

13.81
1233.52
EV-to-EBIT 24.20
ALOG's EV-to-EBIT is ranked higher than
84% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ALOG: 24.20 )
ALOG' s 10-Year EV-to-EBIT Range
Min: -1866   Max: 388.6
Current: 24.2

-1866
388.6
PEG 2.31
ALOG's PEG is ranked higher than
93% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ALOG: 2.31 )
ALOG' s 10-Year PEG Range
Min: 0.81   Max: 213.51
Current: 2.31

0.81
213.51
Shiller P/E 40.59
ALOG's Shiller P/E is ranked higher than
90% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ALOG: 40.59 )
ALOG' s 10-Year Shiller P/E Range
Min: 15.12   Max: 54.28
Current: 40.59

15.12
54.28
Current Ratio 4.68
ALOG's Current Ratio is ranked higher than
86% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. ALOG: 4.68 )
ALOG' s 10-Year Current Ratio Range
Min: 2.82   Max: 7.99
Current: 4.68

2.82
7.99
Quick Ratio 2.93
ALOG's Quick Ratio is ranked higher than
79% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. ALOG: 2.93 )
ALOG' s 10-Year Quick Ratio Range
Min: 2.13   Max: 6.15
Current: 2.93

2.13
6.15

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.46
ALOG's Dividend Yield is ranked lower than
87% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.31 vs. ALOG: 0.46 )
ALOG' s 10-Year Dividend Yield Range
Min: 0.41   Max: 1.6
Current: 0.46

0.41
1.6
Dividend Payout 0.12
ALOG's Dividend Payout is ranked higher than
98% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ALOG: 0.12 )
ALOG' s 10-Year Dividend Payout Range
Min: 0.04   Max: 8
Current: 0.12

0.04
8
Yield on cost (5-Year) 0.50
ALOG's Yield on cost (5-Year) is ranked lower than
88% of the 82 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.48 vs. ALOG: 0.50 )
ALOG' s 10-Year Yield on cost (5-Year) Range
Min: 0.41   Max: 1.6
Current: 0.5

0.41
1.6
Share Buyback Rate -0.30
ALOG's Share Buyback Rate is ranked higher than
85% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.60 vs. ALOG: -0.30 )
ALOG' s 10-Year Share Buyback Rate Range
Min: 3.2   Max: -1.3
Current: -0.3

Valuation & Return

vs
industry
vs
history
Price/Net Cash 49.72
ALOG's Price/Net Cash is ranked higher than
83% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ALOG: 49.72 )
ALOG' s 10-Year Price/Net Cash Range
Min: 3.17   Max: 124.64
Current: 49.72

3.17
124.64
Price/Net Current Asset Value 6.96
ALOG's Price/Net Current Asset Value is ranked higher than
89% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ALOG: 6.96 )
ALOG' s 10-Year Price/Net Current Asset Value Range
Min: 1.91   Max: 23.17
Current: 6.96

1.91
23.17
Price/Tangible Book 2.72
ALOG's Price/Tangible Book is ranked higher than
87% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.25 vs. ALOG: 2.72 )
ALOG' s 10-Year Price/Tangible Book Range
Min: 0.93   Max: 3.17
Current: 2.72

0.93
3.17
Price/DCF (Projected) 1.66
ALOG's Price/DCF (Projected) is ranked higher than
91% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ALOG: 1.66 )
ALOG' s 10-Year Price/DCF (Projected) Range
Min: 0.79   Max: 2.07
Current: 1.66

0.79
2.07
Price/Median PS Value 1.16
ALOG's Price/Median PS Value is ranked higher than
76% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.36 vs. ALOG: 1.16 )
ALOG' s 10-Year Price/Median PS Value Range
Min: 0.44   Max: 1.57
Current: 1.16

0.44
1.57
Price/Peter Lynch Fair Value 1.51
ALOG's Price/Peter Lynch Fair Value is ranked higher than
96% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ALOG: 1.51 )
ALOG' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.82   Max: 11.42
Current: 1.51

0.82
11.42
Price/Graham Number 1.77
ALOG's Price/Graham Number is ranked higher than
94% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ALOG: 1.77 )
ALOG' s 10-Year Price/Graham Number Range
Min: 1   Max: 12.17
Current: 1.77

1
12.17
Earnings Yield (Greenblatt) 4.10
ALOG's Earnings Yield (Greenblatt) is ranked higher than
84% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.00 vs. ALOG: 4.10 )
ALOG' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 8.3
Current: 4.1

0.3
8.3
Forward Rate of Return (Yacktman) 19.54
ALOG's Forward Rate of Return (Yacktman) is ranked higher than
87% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.28 vs. ALOG: 19.54 )
ALOG' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -23.6   Max: 36.8
Current: 19.54

-23.6
36.8

Analyst Estimate

Jul15 Jul16 Jul17
Revenue(Mil) 546 594 660
EPS($) 3.81 4.50 5.72
EPS without NRI($) 3.81 4.50 5.72

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:A, ROP, GRMN, HXGBY, TRMB » details
Traded in other countries:AJM.Germany,
Analogic Corporation was incorporated in the Commonwealth of Massachusetts in November 1967. The company is a technology company that designs and manufactures advanced medical imaging and security systems and subsystems sold to original equipment manufacturers, or OEMs, and end users primarily in the healthcare and airport security markets. Its business is strategically aligned into three segments—Medical Imaging, Ultrasound, and Security Technology—transforming into a unified global business with one mission. Its business segments are described as follows: Medical Imaging, which primarily includes systems and subsystems for CT and MRI medical imaging equipment as well as state-of-the-art, Selenium-based detectors for screening and diagnostic applications in mammography. Ultrasound, which designs, manufactures, and distributes ultrasound systems and transducers primarily in the urology, surgery, robotic assisted surgery, anesthesia, and general imaging markets. Security Technology, which includes advanced threat detecting CT systems utilizing its expertise in advanced imaging technology, primarily sold for baggage screening in airports worldwide. Its manufacturing facilities are subject to numerous environmental laws and regulations, particularly with respect to industrial waste and emissions.
» More Articles for ALOG

Headlines

Articles On GuruFocus.com
Could These Science Stocks Provide Big Gains? Mar 11 2012 
Weekly Top Insider Buys: Health Care REIT Inc., Human Genome Sciences Inc., Conseco Inc., Universal Jan 02 2010 
Analogic Corp. Reports Operating Results (10-K) Sep 29 2009 
Analogic Corp. (ALOG) Files Quarterly Report for the Period Ended on 2008-10-31 Dec 15 2008 
Analogic Corporation Announces Cash Dividend for Its First Quarter Dec 09 2008 
Analogic Corporation Announces Results for Its First Quarter Ended October 31, 2008 Dec 09 2008 

More From Other Websites
ANALOGIC CORP Financials Dec 17 2014
10-Q for Analogic Corp. Dec 12 2014
Analogic Corp. Says Bribery Probe Likely to End in Penalty Dec 12 2014
ANALOGIC CORP Files SEC form 10-Q, Quarterly Report Dec 10 2014
Analogic Corporation Beats Q1 EPS Estimates Dec 09 2014
Analogic Corp Earnings Call scheduled for 5:00 pm ET today Dec 09 2014
Analogic (ALOG) Stock Gains in After-Hours Trading Today Following Earnings Beat Dec 09 2014
ANALOGIC CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Dec 09 2014
Analogic Announces Financial Results for the First Quarter Ended October 31, 2014 and Declares... Dec 09 2014
Analogic posts 1Q profit Dec 09 2014
Analogic posts 1Q profit Dec 09 2014
Analogic Announces Financial Results for the First Quarter Ended October 31, 2014 and Declares... Dec 09 2014
Q1 2015 Analogic Corp Earnings Release - After Market Close Dec 09 2014
Benzinga Weekly Preview: Government Shutdown Deadline Approaching Dec 06 2014
Powerful, New bk3000 Ultrasound System Featured at RSNA Nov 25 2014
Analogic Announces Timing for First Quarter 2015 Earnings Conference Call and Webcast Nov 25 2014
Analogic Announces Timing for First Quarter 2015 Earnings Conference Call and Webcast Nov 25 2014
BK Ultrasound, Powered by Analogic, Enters Emergency Medicine Market Oct 28 2014
BK Ultrasound, Powered by Analogic, Enters Emergency Medicine Market Oct 28 2014
Analogic Introduces the New Flex Focus 400 exp Ultrasound System at Anesthesiology 2014 Oct 10 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK